Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 48

Results For "Director"

2714 News Found

Torrent Pharmaceuticals appoints Aman Mehta as MD
People | July 29, 2025

Torrent Pharmaceuticals appoints Aman Mehta as MD

Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York


Healthians elevates Nishant Singhal as CEO
People | July 28, 2025

Healthians elevates Nishant Singhal as CEO

Singhal brings a powerful blend of operational excellence, investor acumen, and visionary thinking


Granules India CEO K V Sitaram Rao resigns
People | July 27, 2025

Granules India CEO K V Sitaram Rao resigns

Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service


Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%
News | July 27, 2025

Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%

Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution


Indoco receives EU GMP certificate for its sterile manufacturing facility in Goa
News | July 26, 2025

Indoco receives EU GMP certificate for its sterile manufacturing facility in Goa

This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies


Max Lab partners with Stepcare to expand in Bengaluru
Healthcare | July 23, 2025

Max Lab partners with Stepcare to expand in Bengaluru

This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas


Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr
News | July 23, 2025

Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr

Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%


Roche updates on sBLA for Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
Clinical Trials | July 21, 2025

Roche updates on sBLA for Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population


Sarepta refuses to comply with FDA request to stop shipping gene therapy Elevidys
Drug Approval | July 21, 2025

Sarepta refuses to comply with FDA request to stop shipping gene therapy Elevidys

FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths